

1865

**Topic Category:** 4131-ASIP Signal transduction in cancer**First Author:** Chaoyang LiWuhan Institute of Virology, Chinese Academy of Sciences 44 Xiao Hong Shan Zhong Qu Wuhan  
China, People's Republic of**Phone:**

chaoyangli2009@hotmail.com

**First Author is a:** Investigator**First Author is a member of:** American Society for Biochemistry and Molecular Biology**First Author Degree:** PhD, DSc, or equivalent**Presentation Preference:** Oral**Sponsor:** Chaoyang Li**Sponsor Phone:** 862787198750

chaoyangli2009@hotmail.com






**Sponsor's Society:** Biochemistry - American Society for Biochemistry and Molecular Biology (ASBMB) - Host Society**Keywords:** 1. NF $\kappa$ B 2. PrP 3. CYLD**Prion protein is required for tumor necrosis factor alpha (TNF $\alpha$ )-triggered nuclear factor kappa B (NF- $\kappa$ B) signaling and cytokine production.**

Chaoyang Li, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China, People's Republic of


Cellular prion protein (PrP<sup>C</sup>) is a widely expressed, highly conserved glycosylphosphatidylinositol (GPI) anchored protein among mammalian. In some cancer cells, PrP exists as pro-PrP, retaining its GPI-peptide signaling sequence and localizing outside of lipid rafts.

In M2 cells, TNF $\alpha$  upregulates the expression of phosphorylated (p)-I $\kappa$ B-kinase  $\alpha/\beta$  (p-IKK $\alpha/\beta$ ), p-p65, and p-JNK, but downregulates the I $\kappa$ B $\alpha$  protein, all of which are downstream signaling intermediates in the TNF receptor signaling cascade. When *PRNP* is deleted in M2 cells, the effects of TNF $\alpha$  are no longer detectable. More importantly, p-p65 and p-JNK responses are restored when *PRNP* is re-introduced back into the *PRNP* null cells. TNF $\alpha$  also activates NF- $\kappa$ B and increases TNF $\alpha$  production in wildtype M2 cells, but not in PrP-null M2 cells. Similar results are obtained in the BxPC-3 cells. Moreover, TNF $\alpha$  activation of NF- $\kappa$ B requires ubiquitination of receptor-interacting serine/threonine kinase 1 (RIP1) and TNF receptor-associated factor 2 (TRAF2). TNF $\alpha$  treatment increases the binding between PrP and the deubiquitinase tumor suppressor cylindromatosis (CYLD). In these treated cells, binding of CYLD to RIP1 and TRAF2 is reduced. We conclude that PrP traps CYLD, preventing it from binding and deubiquitinating RIP1 and TRAF2, thus activating NF- $\kappa$ B signaling.

These results reveal that PrP enhances the responses to TNF $\alpha$ , promoting proinflammatory cytokine production, which may contribute to inflammation and tumorigenesis.

PrP is required for responses to TNF $\alpha$  signaling in M2 cellsResponse to TNF $\alpha$  treatment is rescued when PRNP is reintroduced into PrP null cellsPrP is required for the transcriptional activity of NF- $\kappa$ B and production of TNF $\alpha$ PrP bound to CYLD to regulate NF- $\kappa$ B signaling

Binding between PrP and CYLD reduces RIP1 and TRAF2 ubiquitination

A model to describe how PrP affect NF $\kappa$ B signaling**Support or Funding Information**

1.NSFC (Awarded number: 81172376): pro-prion contributes to PDAC tumorigenesis. 2.NSFC (Awarded number: 31670170) : Deficiency of GPI Anchor Synthesis Leading to Generation of Pro-PrP.